[1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases

ABSTRACT

The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or prophylaxis of a neurodegenerative or hematological disease or condition, their use as a medicament, especially for treating a neurodegenerative or hematological disease or condition, and a pharmaceutical composition comprising the compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.12/664,130 filed on Dec. 11, 2009, which is a U.S. national phase underthe provisions of 35 U.S.C. §371 of International Patent Application No.PCT/EP08/57319 filed on Jun. 11, 2008, which in turn claims priority ofEuropean Patent Application No. 07380167.2 filed on Jun. 11, 2007. Thedisclosures of U.S. patent application Ser. No. 12/664,130,International Patent Application No. PCT/EP08/57319, and European PatentApplication No. 07380167.2 are hereby incorporated herein by referencein their respective entireties, for all purposes.

FIELD OF THE INVENTION

The present invention relates to the use of some [1,10]-phenanthrolinederivatives for the treatment and/or prophylaxis of a neurodegenerativeor haematological disease or condition, particularly Alzheimer's disease(AD). Additionally, there is provided new [1,10]-phenanthrolinederivatives, a process for preparing such compounds and pharmaceuticalcompositions comprising them.

BACKGROUND OF THE INVENTION

AD and Parkinson's disease (PD) are the most frequent progressiveneurodegenerative diseases affecting millions of people in the world.Because a significant percentage of patients share common clinical andpathological symptoms from both entities, this seems to indicate theexistence of a common pathological mechanism.

Oxidative stress is known to be involved in many diseases, includingatherosclerosis, Parkinson's disease and AD, and may be also importantin ageing.

Reactive oxygen species (ROS), such as oxygen radical superoxide (02) orhydrogen peroxide (H₂O₂), are produced during normal metabolic processesand perform several useful functions (Reactive oxygen species and thecentral nervous system, Halliwell B., J. Neurochem.; 1992, 59 859:1609-1623). Cells are provided with several mechanisms to control levelsof these oxidative agents, for instance, superoxide dismutase (SOD),glutathione or vitamin E. In normal physiological conditions, a balancebetween ROS and these anti-oxidative mechanisms exists. An excessiveproduction of ROS and a loss of efficiency of the anti-oxidativedefences can lead to cellular oxidative stress and thus to pathologicalconditions in cells and provoke tissue damage. This event seems to occurmore dramatically in neurons, because of their high rate of metabolicactivity, and thus seems to be related to a series of degenerativeprocesses, diseases and syndromes, for example, AD, PD, amyotrophiclateral sclerosis (ALS) and schizophrenia (Glutathione, oxidative stressand neurodegeneration, Schulz et al., Eur. J. Biochem.; 2000, 267,4904-4911). Also other diseases or pathological conditions have beenrelated to oxidative stress, such as Huntington's Disease (Oxidativedamage in Huntington's disease, Segovia J. and Pérez-Severiano F,Methods Mol. Biol.; 2004; 207: 321-334), brain injuries, such as strokeand ischemia, (Oxidative Stress in the Context of Acute CerebrovascularStroke, El Kossi et al., Stroke; 2000; 31: 1889-1892), diabetes(Oxidative stress as a therapeutic target in diabetes: revisiting thecontroversy, Wiernsperger N F, Diabetes Metab.; 2003; 29, 579-85),multiple sclerosis (The role of oxidative stress in the pathogenesis ofmultiple sclerosis: the need for effective antioxidant therapy,Gilgun-Sherki Y. et al., J. Neurol.; 2004; 251 (3): 261-8), epilepsy(Oxidative injury in epilepsy: potential for antioxidant therapy?,Costello D. J. and Delanty N., Expert. Rev. Neurother.; 2004;4(3):541-553), atherosclerosis (The oxidative stress hypothesis ofatherogenesis, Iuliano L., Lipids; 2001; 36 suppl: S41-44), Friedreich'sAtaxia (Oxidative stress mitochondrial dysfunction and cellular stressresponse in Friedreich's ataxia, Calabrese et al., J. Neurol. Sci.;2005) and heart failure (Oxygen, oxidative stress, hypoxia and heartfailure, Giordano F. J., J. Clinic. Invest.; 2005; 115 (3): 500-508).Treatments that lead to an enhancement of the anti-oxidative mechanismsmay slow down the progression of some of the mentioned diseases.

Another type of cellular stress is the endoplasmic reticulum (ER)stress. The ER is an intracellular organelle represented by an extensivenetwork formed by cisternae and microtubules and which extends from thenuclear envelope to the cell surface in all eukaryotic cells. ER playsseveral vital functions: the rough ER is the place for protein synthesisand postranslational changes for the correct folding of proteins, ER isthe common transport route to deliver proteins to their properdestination within the cell and it is also a Ca²⁺ reservoir.Disturbances in the function of ER lead to accumulation of unfoldedproteins within the ER, inducing a condition generally referred to as ERstress. These disturbances can be caused not only by biochemicalimbalance but also by disturbance in the ER Ca²⁺ homeostasis. Somestudies (Glycogen synthase kinase 3β (GSK3β) mediates6-hydroxydopamine-induced neuronal death, Chen et al., FASEB J. 2004;18(10):1162-4) demonstrate that ER stress activates the enzyme glycogensynthase kinase 3β, an enzyme involved in the neurodegenerative processoccurred in patients with AD.

The catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) is formedendogenously in patients suffering from Parkinson's disease. 6-OHDA hastwo ways of action: it easily forms free radicals and it is a potentinhibitor of the mitochondrial respiratory chain complexes I and IV.6-hydroxydopamine (6-OHDA) models are used to produce a broad spectrumof neurochemical and behavioural deficits characterising DA degenerationin humans, specially for PD (e.g. Glinka Y et al, “Mechanism of6-hydroxydopamine neurotoxicity”, J Neural Transm Suppl. 1997; 50:55-66;Willis G L et al, “The implementation of acute versus chronic animalmodels for treatment discovery in Parkinson's disease” Rev Neurosci.2004; 15(1):75-87).

A common sign of neurodegenerative diseases is the accumulation anddeposits of misfolded proteins which affect several signalling pathwayswhich lead finally to neuronal death. Some authors (ER stress andneurodegenerative diseases, Lindholm et al., Cell Death andDifferentiation; 2006; 13: 385-392) consider that ER stress is relatedto several neurodegenerative diseases such as, PD, AD, ALS, andtransmissible spongiform encephalopaties (TSEs).

In view of the above, an interesting approach for developing newpharmaceutical compounds for treating neurodegenerative diseases may bedesigning compounds which inhibit cellular oxidative stress.

Amyloid beta (Aβ) is a peptide that is the main constituent of amyloidplaques in the brains of AD patients. Similar plaques appear in somevariants of Lewy body dementia and in inclusion body myositis, a muscledisease. Aβ also forms aggregates coating cerebral blood vessels incerebral amyloid angiopathy.

Aβ is formed after sequential cleavage of the amyloid precursor protein(APP) by the β- and γ-secretases. Either Aβ₄₂ or Aβ₄₀ are produceddepending on where the cleavage occurs. APP is a transmembraneglycoprotein. Autosomal-dominant mutations in APP cause hereditaryearly-onset AD, likely as a result of altered proteolytic processing.Increases in total Aβ levels have been implicated in the pathogenesis ofboth familial and sporadic AD [The American Journal of Pathology; Lue,L; 155(3):853-662 (1999)].

According to the “amyloid hypothesis”, accepted by the majority ofresearchers, the plaques are responsible for the pathology of AD.Intra-cellular deposits of tau protein are also seen in the disease, andmay also be implicated. The oligomers that form on the amyloid pathway,rather than the mature fibrils, may be the cytotoxic species.

Thus, the development of inhibitors of amyloid beta secretion are acurrent strategy to find treatments for diseases in which amyloidosis isinvolved, such as AD, PD, Huntington's disease, TSEs, Prion diseases,Creutzfeldt-Jakob disease and Bovine spongiform encephalopathy.

On the other hand, iron chelators are used to treat some kinds ofhaematological diseases, such as thalassaemia, anaemia, aplasticanaemia, myelodysplastic syndrome, diabetes, Diamond-Blackfan anaemia,sickle cell disease, hematologic disorders which require regular redcell transfusions, iron-induced cardiac dysfunction, and iron-inducedheart failure.

Metals such as iron are capable of redox cycling in which a singleelectron may be accepted or donated by the metal. This action catalyzesreactions that produce reactive radicals and can produce reactive oxygenspecies. The most important reactions are probably Fenton's reaction andthe Haber-Weiss reaction, in which hydroxyl radical is produced fromreduced iron and hydrogen peroxide. The hydroxyl radical then can leadto modifications of amino acids (e.g. meta-tyrosine and ortho-tyrosineformation from phenylalanine), carbohydrates, initiate lipidperoxidation, and oxidize nucleobases. Most enzymes that producereactive oxygen species contain one of these metals. The presence ofsuch metals in biological systems in an uncomplexed form (not in aprotein or other protective metal complex) can significantly increasethe level of oxidative stress. Therefore, it is desirable that chelatingligands for the treatment of conditions according to the invention, showa preference towards Fe(II) rather than Fe(III).

Iron chelators deferoxamine and deferiprone, have been used in humanssince the 1970s and the late 1980s, respectively, and lately a new drug,deferasirox has been used in humans. Deferoxamine has proven efficientin thalassemia major, sickle cell disease and other hematologicdisorders for which hematologic disorders, but can only be administeredsubcutaneously [Blood; Neufeld, E. L., 107(9): 3436-3441 (2006)].Deferasirox, approved in the US for chronic iron overload due to bloodtransfusions, has shown moderate to good success [Hematology; Cohen, A.R., 42-47 (2006)]. Combination therapy with deferiprone and deferoxamineis also being used.

However, side effects have been associated with the use of these drugs;deferiprone often causes gastrointestinal symptoms, erosive arthritis,neutropenia and in some cases agranulocytosis; deferiprone therapyrequires weekly complete blood count and ancillary supplies forinfusion, so close monitoring is required; deferoxamine presentsgastrointestinal symptoms and joint pain and deferasirox is costly.Therefore there still remains a need for additional therapeutic ironchelators for use in these hematological diseases, produced and usedwith low cost and reduced side effects.

It is well known that phenanthroline derivatives exhibit good ironchelating properties. Some phenanthroline derivatives are shown inpatent PL76345. It would be highly recommended to find newphenanthroline derivatives which can show improved properties inchelating iron metal in order to provide an enhanced capability fortreating the haematological mentioned diseases.

SUMMARY OF THE INVENTION

The authors of the present invention have found a new family ofcompounds, namely [1,10]-phenanthroline derivatives, defined by formula(I) as detailed below, which encompasses the properties of protectingfrom oxidative stress, particularly from hydrogen peroxide-cell deathand 6-hydroxydopamine-cell death, having a neuroprotective effectagainst Aβ toxicity, and inhibiting Aβ secretion. Surprisingly, theinventors have found that the compounds of the invention are capable ofcrossing the brain blood bather. They may thus be useful for thetreatment or prophylaxis of neurodegenerative diseases or conditions. Inaddition, these compounds are characterized for acting as specific iron(II) chelators and therefore they could also be used to treathaematological diseases.

Therefore, according to a first aspect, the present invention isdirected to the use of a compound of formula (I):

wherein R¹ is selected from —S—R³, —O—R⁴ and halogen;R⁷ is selected from —CH═N—OR⁸ or —CHO;R³ and R⁴ are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅ aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅ aryl, halogen, preferably by 1 to 6 halogen atoms, morepreferably 1 to 3, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxy and/or —NR⁵R⁶,R⁵ and R⁶ being independently selected from hydrogen and C₁-C₆ alkyl,R⁸ is selected from hydrogen and C₁-C₆ alkyl;or any salt or solvate or stereoisomer or tautomer thereof,in the preparation of a medicament for the treatment or prophylaxis of aneurodegenerative or haematological disease or condition.

Thus an aspect of the invention are the compounds of formula (I) asdefined above for the treatment or prophylaxis of a neurodegenerative orhaematological disease or condition.

The compounds of formula (I) may be used in biological assays whereinbeta-amyloid secretion needs to be modulated. Therefore, in anotheraspect, the invention refers to the use of a compounds of formula (I) asdefined above, or any salt or solvate thereof, as reagent for biologicalassays, preferably as a reactive for pharmacokinetic assays, blood brainbarrier crossing assays, chelation assays, for essays on protectionagainst hydrogen peroxide-induced cell death, protection against6-OHDA-induced cell death, neuroprotection against Aβ toxicity andinhibiton of beta-amyloid secretion.

A further aspect of the invention refers to a method of treating orpreventing a disease or condition, said method comprises administeringto a patient in need of such a treatment a therapeutically effectiveamount of at least one compound of formula (I) as defined above, itssalts, solvates, stereoisomers or tautomers thereof, or a pharmaceuticalcomposition thereof.

According to a further aspect, the present invention is directed to acompound of formula (I)

wherein R¹ is selected from —S—R³, —O—R⁴ and halogen;R⁷ is selected from —CH═N—OR⁸ or —CHO;R³ and R⁴ are independently selected from the group consisting of C₁-C₆alkyl, C₆-C₁₅ aryl and heteroaryl, optionally substituted by C₁-C₆alkyl, C₆-C₁₅ aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxy and/or—NR⁵R⁶,R⁵ and R⁶ being independently selected from hydrogen and C₁-C₆ alkyl,R⁸ is selected from hydrogen and C₁-C₆ alkyl;or any salt or solvate or stereoisomer or tautomer thereof,with the proviso that when R¹ is Cl, then R⁷ is not —CHO.

Another aspect of the present invention refers to a pharmaceuticalcomposition comprising at least one compound of formula (I) as definedabove, its salts or solvates or stereoisomers or tautomers thereof, andat least one pharmaceutically acceptable carrier.

According to a further aspect, the present invention is directed to acompound of formula (I) as defined above, its salts, solvates orstereoisomers or tautomers thereof, for use as a medicament.

According to a further aspect, the present invention is directed to aprocess for the synthesis of the compounds of formula I, its salts orsolvates or stereoisomers or tautomers thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an absorbance spectrum of compounds 4, 7, 8 and 10 in absenceand presence of Fe(III). PBS 10 mM, pH 7.4. Concentration of ligand andFe(III), 200 μM.

FIG. 2 is an absorbance spectrum of the complex Fe(II)-Compound 4.Concentration of Fe(II) and Compound 4, 200 μM, PBS 10 mM, pH 8.

FIG. 3 is an absorbance spectrum of the complex Fe(II)-Compound 7.Concentration of Fe(II) and Compound 7, 400 μM, PBS 10 mM, pH 8.

FIG. 4 is an absorbance spectrum of the complex Fe(II)-Compound 8.Concentration of Fe(II) and Compound 8, 200 μM, PBS 10 mM, pH 7.4.

FIG. 5 is an absorbance spectrum of the complex Fe(II)-Compound 10.Concentration of Fe(II) and Compound 10, 100 μM, PBS 10 mM, pH 7.4.

FIG. 6 depicts the absorbance spectra of the mixture of Cu (II) and eachof the quelating ligands (Compound 4, Compound 7, Compound 8).Concentration of Cu(II) and all compounds 200 μM, PBS 10 mM, pH 7.4.

FIG. 7 is the absorbance spectra of the complex Cu(II)-Compound 10.Concentration 200 μM, PBS 10 mM, pH 7.4.

FIG. 8 represents the absorbance spectra of the complex Zn(II)-Compound4. Concentration 200 μM, PBS 10 mM, pH 7.4.

FIG. 9 shows the absorbance spectra of the complex Zn(II)-Compound 7.Concentration 180 μM, PBS 10 mM, pH 7.4.

FIG. 10 shows the absorbance spectra of the complex Zn(II)-Compound 8.Concentration 100 μM, PBS 10 mM, pH 7.4.

FIG. 11 shows the absorbance spectra of the complex Zn(II)-Compound 10.Concentration 20 μM, PBS 10 mM, pH 7.4.

DETAILED DESCRIPTION OF THE INVENTION

In the above definition of compounds of formula (I) the following termshave the meaning indicated:

“C₁-C₆ Alkyl” refers to a linear or branched hydrocarbon chain radicalconsisting of carbon and hydrogen atoms, containing no unsaturation,having one to six carbon atoms, preferably one to three, and which isattached to the rest of the molecule by a single bond, e.g., methyl,ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc.

“C₁-C₆ alkoxy” refers to a radical of the formula —OR_(a) where R_(a) isa “C₁-C₆ alkyl” radical as defined above, e.g., methoxy, ethoxy,propoxy, etc.

“Halogen” refers to bromo, chloro, iodo or fluoro.

“Aryl” refers to an aromatic hydrocarbon radical having 6 to 15,preferably 6 to 10 carbon atoms such as phenyl or naphthyl.

“Heteroaryl” refers to a stable 3- to 15-membered ring system wherein atleast one of the rings is aromatic, and which consists of carbon atomsand from one to five heteroatoms, preferably one to three, selected fromthe group consisting of nitrogen, oxygen, and sulphur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5- or6-membered ring with one or more heteroatoms, preferably one to three.For the purposes of this invention, the heteroaryl may be a monocyclic,bicyclic or tricyclic ring system, which may include fused ring systems;and the nitrogen, carbon or sulfur atoms in the heteroaryl radical maybe optionally oxidised; the nitrogen atom may be optionally quaternized;Examples of such heteroaryles include, but are not limited to thiazol,thiadiazol, benzimidazole, benzothiazole, furan, isothiazole orimidazole,

Uses of Compounds of Formula (I)

According to one embodiment, the invention is directed to the use of acompound of formula (I), wherein

-   -   R¹ is selected from —S—R³, —O—R⁴ and halogen;    -   R⁷ is selected from —CH═N—OR⁸ or —CHO;    -   R³ and R⁴ are independently a C₁-C₆ alkyl, optionally        substituted by C₁-C₆ alkoxy and/or —NR⁵R⁶,    -   R⁵ and R⁶ being independently selected from hydrogen and C₁-C₆        alkyl,    -   R⁸ is selected from hydrogen and C₁-C₆ alkyl.

Within the frame of the present invention, the expression“neurodegenerative disease or condition” means any disease or conditionin which neurodegeneration occurs. Such disease or condition includes,but is not limited to, any disease or condition selected fromAlzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis(ALS), schizophrenia, Huntington's Disease, brain injuries, such asstroke and ischemia, multiple sclerosis, epilepsy, Friedreich's Ataxia,spongiform encephalopaties, amyloidosis, vascular dementia, tauophaties,progressive supranuclear palsy, frontotemporal lobular degeneration,subacute sclerosing panencephalitic parkinsonism, postencephaliticparkinsonism, pugilistic encephalitis, guam parkinsonism-dementiacomplex, Pick's disease, corticobasal degeneration, frontotemporaldementia, AIDS associated dementia, multiple sclerosis, mood disorderssuch as depression, schizophrenia and bipolar disorders, promotion offunctional recovery post stroke and brain injury, especially traumaticbrain injury. In a preferred aspect of the invention, theneurodegenerative disease or condition is Alzheimer's Disease.

Within the frame of the present invention, the expression“haematological disease or condition” means any disease or condition inwhich disorders of the blood and blood forming tissues occurs. In apreferred embodiment, the haematological disease or condition isselected from thalassaemia, anaemia, aplastic anaemia, Diamond-Blackfananemia, sickle cell disease, hematologic disorders which require regularred cell transfusions, myelodysplastic syndrome, iron-induced cardiacdysfunction, iron-induced heart failure, and diabetes, more preferablyfrom thalassaemia, anaemia, aplastic anaemia, myelodysplastic syndromeand diabetes.

In a particular aspect, the compound of formula (I) used in the presentinvention is selected from the following compounds:

-   4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Chloro-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Chloro-[1,10]phenanthroline-2-carbaldehyde-   4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide-   4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   [2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic    acid methyl ester-   4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime-   [2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic    acid-   4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-([1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde-   4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde-   4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde    or its salts, solvates or stereoisomers or tautomers thereof.

The compounds used in the present invention may be used with at leastother drug to provide a combination therapy. The at least other drug mayform part of the same composition, or be provided as a separatecomposition for administration at the same time or at different time.

According to a further aspect, the present invention is directed to amethod of treating or preventing a neurodegenerative or haematologicaldisease or condition, said method comprises administering to a patientin need of such a treatment a therapeutically effective amount of atleast one compound of formula (I), its salts or solvates, stereoisomersor tautomers thereof, as defined above or a pharmaceutical compositionthereof.

The term “treatment” or “to treat” in the context of this specificationmeans administration of a compound or formulation according to theinvention to prevent, ameliorate or eliminate the disease or one or moresymptoms associated with said disease. “Treatment” also encompassespreventing, ameliorating or eliminating the physiological sequelae ofthe disease.

The term “ameliorate” in the context of this invention is understood asmeaning any improvement on the situation of the patient treated—eithersubjectively (feeling of or on the patient) or objectively (measuredparameters).

Compounds of Formula I

An embodiment of the invention is directed to a compound of formula (I)wherein

-   -   R¹ is selected from —S—R³, —O—R⁴ and halogen;    -   R⁷ is selected from —CH═N—OR⁸ or —CHO;    -   R³ and R⁴ are independently a C₁-C₆ alkyl, optionally        substituted by C₁-C₆ alkoxy and/or —NR⁵R⁶,    -   R⁵ and R⁶ being independently selected from hydrogen and C₁-C₆        alkyl,    -   R⁸ is selected from hydrogen and C₁-C₆ alkyl;    -   or any salt or solvate or stereoisomer thereof,    -   with the proviso that when R¹ is Cl or OCH₃, then R⁷ is not —CHO        or —CH═N—OH.

Preferred compounds are those wherein R⁷ is —CH═N—OR⁸, wherein R⁸ isselected from hydrogen and C₁-C₆ alkyl. More preferably R⁸ is hydrogen.

Other preferred compounds are those wherein R¹ is —S—R³, wherein R³ isC₁-C₆ alkyl, optionally substituted by C₁-C₆ alkyl and/or NR⁵R⁶, beingR⁵ and R⁶ independently selected from hydrogen and C₁-C₆ alkyl. Evenmore preferred compounds are those wherein R³ is selected from methyl,ethyl, propyl and isopropyl.

In another preferred embodiment, R¹ is —O—R⁴, wherein R⁴ is C₁-C₆ alkyl,optionally substituted by C₁-C₆ alkyl and/or NR⁵R⁶, being R⁵ and R⁶independently selected from hydrogen and C₁-C₆ alkyl. Preferably, R⁴ isselected from methyl and ethyl. Even more preferably, R⁴ is ethylsubstituted by —NR⁵R⁶ or methoxy, being R⁵ and R⁶ independently selectedfrom hydrogen and C₁-C₆ alkyl. Within this preferred embodiment theamine —NR⁵R⁶ is primary or tertiary, being more preferably diethylamine.

In a further preferred embodiment, the double bond of the oxime group—CH═NOR⁸ presents E-conformation as shown below:

According to a further embodiment, R¹ is chloro.

According to a further embodiment, R¹ is —S-heteroaryl, wherein theheteroaryl group is optionally substituted by C₁-C₆ alkyl, preferablyC₁-C₃ alkyl, C₆-C₁₅ aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxyand/or —NR⁵R⁶.

According to a further embodiment, R³ is a C₁-C₃ alkyl group substitutedby —(C═O)NR⁵R⁶ or —(C═O)OR⁵.

According to a preferred embodiment, the compound of formula (I) isselected from the following compounds:

-   4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime-   4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide-   4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   [2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic    acid methyl ester-   4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime-   [2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic    acid-   4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-[1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde    oxime-   4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime-   4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde-   4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde-   4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde-   4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde and    salts or solvates or stereoisomers or tautomers thereof.

The compounds of formula (I) may be in the form of salts, preferablypharmaceutically acceptable salts, or in the form of solvates. The term“pharmaceutically acceptable salts” refers to any salt which uponadministration to the recipient is capable of providing (directly orindirectly) a compound as described herein. However, it will beappreciated that non-pharmaceutically acceptable salts also fall withinthe scope of the invention since those may be useful in the preparationof pharmaceutically acceptable salts. Preferably, “pharmaceuticallyacceptable” refers to molecular entities and compositions that arephysiologically tolerable and do not typically produce an allergic orsimilar untoward reaction, such as gastric upset, dizziness and thelike, when administered to a human. Preferably, as used herein, the term“pharmaceutically acceptable” means approved by a regulatory agency ofthe Federal or a state government or listed in the U.S. Pharmacopeia orother generally recognized pharmacopeia for use in animals, and moreparticularly in humans.

The term “solvate” according to this invention is to be understood asmeaning any form of the active compound according to the invention whichhas another molecule (most likely a polar solvent) attached to it vianon-covalent bonding. Examples of solvates include hydrates andalcoholates, e.g. methanolate. Preferably, the solvates arepharmaceutically acceptable solvates.

The preparation of salts and solvates can be carried out by methodsknown in the art. For instance, pharmaceutically acceptable salts ofcompounds provided herein are synthesized from the parent compound,which contains a basic moiety, by conventional chemical methods.Generally, such salts are, for example, prepared by reacting the freebase forms of these compounds with a stoichiometric amount of theappropriate base or acid in water or in an organic solvent or in amixture of the two. Generally, non-aqueous media like ether, ethylacetate, ethanol, isopropanol or acetonitrile are preferred. Examples ofthe acid addition salts include mineral acid addition salts such as, forexample, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate,phosphate, and organic acid addition salts such as, for example,acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate,malate, mandelate, methanesulphonate and p-toluenesulphonate.

One preferred pharmaceutically acceptable form is the crystalline form,including such form in a pharmaceutical composition. In the case ofsalts and solvates the additional ionic and solvent moieties must alsobe non-toxic. The compounds of the invention may present differentpolymorphic forms, it is intended that the invention encompasses allsuch forms.

The compounds of the invention are also meant to include compounds whichdiffer only in the presence of one or more isotopically enriched atoms.For example, compounds having the present structures except for thereplacement of a hydrogen by a deuterium or tritium, or the replacementof a carbon by a ¹³C- or ¹⁴C-enriched carbon or a nitrogen by¹⁵N-enriched nitrogen are within the scope of this invention.

The compounds of the present invention represented by the abovedescribed formula (I) may include enantiomers depending on the presenceof chiral centres or isomers depending on the presence of multiple bonds(e.g. Z, E). The single isomers, enantiomers or diastereoisomers andmixtures thereof fall within the scope of the present invention.

Pharmaceutical Compositions

According to a further aspect, the present invention is directed to apharmaceutical composition comprising at least one compound of formula(I) as defined above, its salts or solvates or stereoisomers ortautomers thereof, and at least one pharmaceutically acceptable carrier.

The term “carrier” refers to a diluent, adjuvant, excipient, or vehiclewith which the active ingredient is administered. Such pharmaceuticalcarriers can be sterile liquids, such as water and oils, including thoseof petroleum, animal, vegetable or synthetic origin, such as peanut oil,soybean oil, mineral oil, sesame oil and the like. Water or aqueoussolution saline solutions and aqueous dextrose and glycerol solutionsare preferably employed as carriers, particularly for injectablesolutions. Suitable pharmaceutical carriers are described in“Remington's Pharmaceutical Sciences” by E. W. Martin, 1995.

Preferably, the carriers of the invention are approved by a regulatoryagency of the Federal or a state government or listed in the U.S.Pharmacopeia or other generally recognized pharmacopeia for use inanimals, and more particularly in humans

The carriers and auxiliary substances necessary to manufacture thedesired pharmaceutical form of administration of the pharmaceuticalcomposition of the invention will depend, among other factors, on theelected administration pharmaceutical form. Said pharmaceutical forms ofadministration of the pharmaceutical composition will be manufacturedaccording to conventional methods known by the skilled person in theart. A review of different active ingredient administration methods,excipients to be used and processes for producing them can be found in“Tratado de Farmacia Galénica”, C. Faulí i Trillo, Luzán 5, S.A. deEdiciones, 1993.

Examples of pharmaceutical compositions include any solid (tablets,pills, capsules, granules etc.) or liquid (solutions, suspensions oremulsions) compositions for oral, topical or parenteral administration.

In a preferred embodiment the pharmaceutical compositions are in oralform. Suitable dose forms for oral administration may be tablets andcapsules and may contain conventional excipients known in the art suchas binding agents, for example syrup, acacia, gelatin, sorbitol,tragacanth, or polyvinylpyrrolidone; fillers, for example lactose,sugar, maize starch, calcium phosphate, sorbitol or glycine; tablettinglubricants, for example magnesium stearate; disintegrants, for examplestarch, polyvinylpyrrolidone, sodium starch glycolate ormicrocrystalline cellulose; or pharmaceutically acceptable wettingagents such as sodium lauryl sulfate.

The solid oral compositions may be prepared by conventional methods ofblending, filling or tabletting. Repeated blending operations may beused to distribute the active agent throughout those compositionsemploying large quantities of fillers. Such operations are conventionalin the art. The tablets may for example be prepared by wet or drygranulation and optionally coated according to methods well known innormal pharmaceutical practice, in particular with an enteric coating.

The pharmaceutical compositions may also be adapted for parenteraladministration, such as sterile solutions, suspensions or lyophilizedproducts in the appropriate unit dosage form. Adequate excipients can beused, such as bulking agents, buffering agents or surfactants.

The mentioned formulations will be prepared using standard methods suchas those described or referred to in the Spanish and US Pharmacopoeiasand similar reference texts.

The compounds or compositions of the present invention may beadministered by any suitable method, such as intravenous infusion, oralpreparations, and intraperitoneal and intravenous administration. Oraladministration is preferred because of the convenience for the patientand the chronic character of many of the diseases to be treated.

Generally an effective administered amount of a compound of theinvention will depend on the relative efficacy of the compound chosen,the severity of the disorder being treated and the weight of thesufferer. However, active compounds will typically be administered onceor more times a day for example 1, 2, 3 or 4 times daily, with typicaltotal daily doses in the range of from 0.01 to 1000 mg/kg/day.

According to a further aspect, the present invention is directed to acompound of formula (I), its salts or solvates or stereoisomers ortautomers thereof, as defined above, for use as a medicament.

Process for the Synthesis of a Compound of Formula I

The compounds of the present invention may be prepared by a combinationof reactions known in the art.

In a particular embodiment, the compounds of formula (I) can be preparedby a process comprising:

-   a) oxidizing the methyl group of the compound of formula (II) with    an oxidizing agent to form a compound of formula (I):

-   -   wherein R¹ is selected from —SR³, —OR⁴ and halogen, being R³ and        R⁴ independently selected from the group consisting of C₁-C₆        alkyl, C₆-C₁₅ aryl and heteroaryl, optionally substituted by        C₁-C₆ alkyl, C₆-C₁₅ aryl, halogen, —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆        alkoxy and/or —NR⁵R⁶; and wherein R⁵ and R⁶ are independently        selected form hydrogen and C₁-C₆-alkyl,    -   and optionally,

-   b) converting the aldehyde group —CHO in the compound of formula (I)    into an oxime group —CH═N—OR⁸, being R⁸ selected from hydrogen and    C₁-C₆ alkyl, in the presence of hydroxylamine or    O—(C₁-C₆)alkylhydroxylamine:

According to a preferred embodiment the oxidation in step a) is carriedout in the presence of oxidising agents well known to the person skilledin the art. The election of the most suitable reagent is a matter ofroutine experimentation for said person skilled. However, according to apreferred embodiment, the oxidation reaction is carried out in thepresence of SeO₂. The solvent used in said step a) can be, but is notlimited to, dioxane.

According to another preferred embodiment the step b) can be carried outin a mixture of an alcohol, such as ethanol, and an aqueous sodium salt,such as sodium hydroxide.

In a further aspect, the present invention refers to a process for thepreparation of a compound of formula (I) which comprises:

-   -   a) reacting the compound formula (III) with a sodium salt of the        corresponding alcoxide or thiolate of formula —OR³ or —OR⁴, to        form a compound of formula (II):

-   -   -   wherein        -   X is an halogen;

    -   R¹ is selected from —S—R³, —O—R⁴ and halogen;        -   R³ and R⁴ are independently selected from the group            consisting of C₁-C₆ alkyl, C₆-C₁₅ aryl and heteroaryl,            optionally substituted by C₁-C₆ alkyl, C₆-C₁₅ aryl, halogen,            —(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxy and/or —NR⁵R⁶;        -   provided that when R¹ in the formula (II) is an halogen this            step is omitted;

    -   b) oxidising the methyl group of the compound of formula (II)        with an oxidizing agent to form a compound of formula (I);

-   -   -   wherein R¹ is as defined in step a);

    -   and, optionally

    -   c) converting the aldehyde group —CHO in the compound of        formula (I) into an oxime group —CH═N—OR⁸, being R⁸ selected        from hydrogen and C₁-C₆ alkyl, in the presence of hydroxylamine        or O—(C₁-C₆)alkylhydroxylamine:

-   -   -   wherein R¹ is as defined in step a).

The corresponding alkoxide or thiolate as defined is step a) resultsfrom the reaction of the corresponding alcohol or thiol with a suitableinorganic sodium salt. In a preferred embodiment, the sodium salt issodium ethoxide, sodium 2-propanethiolate or sodium 1-propanethiolate.

In another preferred embodiment of this process, step a) is carried outin an alcohol or tetrahydrofurane as solvent.

The starting compound of formula (III) can be prepared by methods knownby a skilled person. For example, it may be synthesized by firstreacting the compound quinolin-8-ylamine with ethyl acetoacetate in thepresence of hydrochloride acid as catalyst to form2-methyl-[1,10]phenanthrolin-4-ol, according to the process described inProc. R. Soc. N.S.W. 1938, 71, 462-474. Subsequently, the phenanthrolineobtained in the first reaction is subjected to an halogenation reaction,such as for example in the presence of POCl₃, to form the compound offormula (III), according to the process described in J. Med. Chem.,2003, 46, 4463-4476.

In the following, the present invention is further illustrated byexamples. They should in no case be interpreted as a limitation of thescope of the invention as defined in the claims.

EXAMPLES

In the present examples, the following compounds of formula (I) arebeing referred to:

Synthesis of the Compounds

Compounds of formula (I) according to the present invention wereprepared following the general preparation strategy detailed below.

In the following, the particular syntheses of compounds 4 to 10, withstructures as detailed in table 1, are described.

The compounds 4 to 10 were synthesized starting from a commonintermediate for which the method of preparation is described below.

Synthesis of the intermediate 4-chloro-2-methyl-[1,10]phenanthroline 1.Preparation of 2-Methyl-[1,10]phenathrolin-4-ol

Synthetic procedure was adapted from Hazlewood, S. J.; Hughes, G. K.;Lions F., J. Proc. R. Soc. N. S. W. 1938, 71, 462-474.

In a 100 mL round-bottomed flask 8-aminoquinoline (15.00 g, 104.0 mmol)and ethyl acetoacetate (13.50 g, 104.0 mmol) were stirred at 100° C. for24 hours in the presence of a catalytic amount of 1N HCl (10 drops). Thereaction mixture was allowed to reach room temperature and toluene (20mL) was added, which was later removed in a rotary evaporator. The sameprocess of dilution with toluene and solvent removal was repeated atleast three times. The dark oily crude enamine obtained was dissolved indiphenyl ether (20 mL) and was transferred to an addition funnelconnected to a 250 mL round-bottomed flask containing diphenyl ether(100 mL). The flask was heated to reflux and the enamine solution wasslowly added over a period of 15 minutes, and reflux was maintained foradditional 20 minutes. The reaction mixture was cooled down to roomtemperature and the crystalline material formed was filtered, washedwith ethyl ether and dried. A light brown solid (10.20 g, 47% yield) wasobtained.

2. Preparation of 4-Chloro-2-methyl-[1,10]phenanthroline

Synthetic procedure was adapted from Harrison R. J.; Cuesta J.;Chessari, G.; Read M. A.; Basra, S. K.; Reszka, A. P.; Morrell, J.;Gowan, S. M.; Incles, C. M.; Tanious, F. A.; Wilson, W. D.; Kelland, L.R.; Neidle, S., J. Med. Chem. 2003, 46, 4463-4476.

To a 500 mL round-bottomed flask equipped with a reflux condensercontaining 2-methyl-[1,10]phenathrolin-4-ol, (10.20 g, 48.5 mmol), wasslowly added phosphorus oxychloride (200 mL) and the mixture wasrefluxed for 3 hours. The reaction flask was allowed to cool down toroom temperature and the solvent was removed in a rotary evaporator. Thesolid obtained was treated with methylene chloride (200 mL) andsaturated NaHCO₃ (200 mL) and transferred to a separatory funnel. Theaqueous layer was further extracted with methylene chloride (200 mL) andthe combined organic layers were washed with brine (200 mL), dried(Na₂SO₄), filtered and concentrated. The residue obtained was treatedwith ethyl ether (100 mL), filtered and dried yielding a light brownsolid (9.00 g). A second crop of 0.60 g of material was obtained fromthe mother liquors as a light yellow solid, with an overall yield of9.60 g (87% yield).

Example 1 Preparation of4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime (Compound4) 1. Synthesis of 2-Methyl-4-methylsulfanyl-[1,10]phenanthroline

Solid sodium methanethiolate (3.30 g, 47.7 mmol) was added to a 100 mLround-bottomed flask containing a solution of4-chloro-2-methyl-[1,10]phenanthroline (intermediate obtainedpreviously), (2.10 g, 9.4 mmol) in methanol (50 mL). The reactionmixture was refluxed for 18 hours and allowed to cool down to roomtemperature afterwards. The solvent was removed in a rotary evaporatorand the residue was treated with methylene chloride (100 mL) andsaturated NaHCO₃ (100 mL) and transferred to a separatory funnel. Theorganic layer was washed with brine (100 mL), dried (Na₂SO₄), filteredand concentrated in vacuo. The solid residue was treated with ethylether, filtered and dried, yielding 1.90 g of a light brown solid (84%).

2. Synthesis of 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (2.18 g, 19.6 mmol) in a mixture of dioxane (100 mL)and water (4 mL) was heated to reflux in a two-neck 250 mLround-bottomed flask. A solution of2-methyl-4-methylsulfanyl-[1,10]phenanthroline (1.89 g, 7.90 mmol) inhot dioxane (100 mL) was added through an addition funnel over a periodof 1 hour and the reaction mixture was refluxed for additional 45minutes. The reaction mixture was filtered while hot and the residuerinsed with more hot dioxane (20 mL) and filtered. The filtrate wasconcentrated in vacuo and the residue obtained was redissolved in hotwater, stirred with decolorizing charcoal and filtered. The filtrate wasallowed to reach room temperature and basified with saturated NaHCO₃until precipitation of a white solid, which was filtered, washed withcold water and dried in vacuo. A white solid (0.80 g, 41% yield) wasobtained.

3. Synthesis of 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehydeoxime

To a 25 mL round-bottomed flask containing a solution of4-methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde (228.0 mg, 1.1mmol) in ethanol (3.2 mL), a solution of hydroxylamine hydrochloride(707.0 mg, 10.2 mmol) in water (5.0 mL) was added followed by theaddition of 10% NaOH until a precipitate was formed. The reactionmixture was heated to 90° for about 30 minutes, cooled to roomtemperature and the white precipitate was filtered, washed with coldwater and dried. White solid (240.0 mg, 100%) was obtained.

¹H NMR (DMSO-d₆, 400 MHz):

11.95 (s, 1H); 9.12 (dd, 1H, J=1.6, 4.2 Hz); 8.50 (dd, 1H, J=1.6, 8.1Hz); 8.33 (s, 1H); 8.06 (AB system, 2H, S_(AB)=9.1 Hz); 7.92 (s, 1H);7.78 (dd, 1H, J=4.2, 8.1 Hz); 2.72 (s, 3H)

¹³C NMR (DMSO-d₆, 100 MHz):

151.2; 150.3; 149.1; 148.5; 145.1; 144.2; 136.2; 128.4; 127.1; 125.3;123.5; 121.1, 121.0; 112.5; 13.4

Example 2 Synthesis of4-Propylsulfanyl-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound5) 1. Synthesis of 2-Methyl-4-propylsulfanyl-[1,10]phenanthroline

Solid sodium 1-propanethiolate (2.35 g, 24.0 mmol) was added to a 100 mLround-bottomed flask containing a solution of4-chloro-2-methyl-[1,10]phenanthroline (1.10 g, 4.8 mmol) in methanol(50 mL). The reaction mixture was refluxed for 18 hours and allowed toreach room temperature. The solvent was removed in a rotary evaporatorand the residue was treated with methylene chloride (100 mL) andsaturated NaHCO₃ (100 mL) and transferred to a reparatory funnel. Theorganic layer was washed with brine (100 mL), dried (Na₂SO₄), filteredand concentrated in vacuo. The solid residue was treated with ethylether, filtered, and dried yielding 0.98 g of a dark orange solid (76%).

2. Synthesis of 4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (0.98 g, 8.8 mmol) in a mixture of dioxane (50 mL)and water (2 mL) was heated to reflux in a two-neck 250 mLround-bottomed flask. A solution of2-methyl-4-propylsulfanyl-[1,10]phenanthroline (0.95 g, 3.5 mmol) in hotdioxane (50 mL) was added through an addition funnel over a period of 30minutes and the reaction mixture was refluxed for additional 1 hour. Thereaction mixture was filtered while hot and the residue rinsed with morehot dioxane (20 mL) and filtered. The filtrates were combined andevaporated in vacuo and the residue was treated with methylene chloride(100 mL) and a 10% K₂CO₃ aqueous solution (100 mL). The aqueous layerwas extracted several times with methylene chloride (3×100 mL) and thecombined organic layers were washed with brine, dried (Na₂SO₄), filteredand concentrated. The crude product was purified by flash chromatography(neutral Al₂O₃, MeOH/DCM, 1:50 to 1:15) to afford the pure product as abrown solid (0.27 g, 27%).

3. Synthesis of 4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehydeoxime

The final step to obtain the Compound 5 is carried out in the same wayas described in the synthesis of Compound 4.

¹H NMR (DMSO-d₆, 400 MHz):

11.96 (s, 1H); 9.11 (dd, 1H, J=1.6, 4.0 Hz); 8.49 (dd, 1H, J=1.6, 8.0Hz); 8.33 (s, 1H); 8.10 (d, 1H, J=9.2 Hz); 8.03 (d, 1H, J=9.2 Hz); 7.96(s, 1H); 7.78 (dd, 1H, J=4.0, 8.0 Hz); 3.23 (t, 2H, J=7.2 Hz); 1.79 (m,2H); 1.08 (t, 3H, J=7.2 Hz)

¹³C NMR (DMSO-d₆, 100 MHz):

151.09; 150.29; 149.14; 147.45; 145.17; 144.54; 136.20; 128.42; 127.09;125.59; 123.50; 121.25; 113.31; 32.19; 21.00; 13.28

Example 3 Preparation of 4-Ethoxy-[1,10]-phenanthroline-2-carbaldehydeoxime (Compound 6) 1. Synthesis of2-Methyl-4-ethoxy-[1,10]phenanthroline

Solid sodium ethoxide (2.97 g, 48.0 mmol) was added to a 100 mLround-bottomed flask containing a solution of4-chloro-2-methyl-[1,10]-phenanthroline (1.10 g, 4.8 mmol) in ethanol(50 mL). The reaction mixture was refluxed for 18 hours. The solvent wasremoved in a rotary evaporator and the residue was treated withmethylene chloride (100 mL) and saturated NaHCO₃ (100 mL) andtransferred to a separatory funnel. The organic layer was washed withbrine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. Thesolid residue was treated with ethyl ether, filtered, and dried yielding0.89 g of a brown solid (78%).

2. Synthesis of 4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (1.01 g, 9.1 mmol) in a mixture of dioxane (50 mL)and water (2 mL) was heated to reflux in a two-neck 250 mLround-bottomed flask. A solution of2-methyl-4-ethoxy-[1,10]phenanthroline (0.87 g, 3.6 mmol) in hot dioxane(50 mL) was added through an addition funnel over a period of 30 minutesand the reaction mixture was refluxed for 1 hour. The reaction mixturewas filtered while hot and the residue rinsed with more hot dioxane (20mL) and filtered. The filtrates were combined and concentrated in vacuoand the residue was treated with methylene chloride (100 mL) and a 10%K₂CO₃ aqueous solution (100 mL). The aqueous layer was extracted withmethylene chloride (3×100 mL) and the combined organic layers werewashed with brine, dried (Na₂SO₄), filtered and concentrated. The crudeproduct was purified by flash chromatography (SiO₂, MeOH/DCM, 1:30 to1:15) to afford the pure product as a light brown solid (0.15 g, 16%).

3. Synthesis of 4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 6 is carried out in the same wayas described in the synthesis of Compound 4.

¹H NMR (DMSO-d₆, 400 MHz):

11.85 (s, 1H); 9.10 (dd, 1H, J=1.6, 4.0 Hz); 8.48 (dd, 1H, J=1.6, 8.0Hz); 8.32 (s, 1H); 8.17 (d, 1H, J=9.2 Hz); 7.96 (d, 1H, J=9.2 Hz); 7.76(dd, 1H, J=4.0, 8.0 Hz); 7.57 (s, 1H); 4.39 (q, 2H, J=6.8 Hz); 1.52 (t,3H, J=6.8 Hz)

¹³C NMR (DMSO-d₆, 100 MHz):

160.85; 153.28; 149.96; 149.61; 146.06; 144.96; 136.15; 128.61; 126.05;123.27; 120.27; 119.57; 99.11; 64.34; 14.22

Example 4 Preparation of4-Isopropylsulfanyl-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound7) 1. Synthesis of 2-Methyl-4-isopropylsulfanyl-[1,10]phenanthroline

Solid sodium 2-propanethiolate (2.35 g, 24.0 mmol) was added to a 100 mLround-bottomed flask containing a solution of4-chloro-2-methyl-[1,10]phenanthroline (1.10 g, 4.8 mmol) in methanol(50 mL). The reaction mixture was refluxed for 18 hours. The solvent wasremoved in a rotary evaporator and the residue was treated withmethylene chloride (100 mL) and saturated NaHCO₃ (100 mL) andtransferred to a separatory funnel. The organic layer was washed withbrine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo. Theresidue was purified by flash chromatography (SiO₂, MeOH/DCM, 1:80) toafford the pure product as a yellow oil (1.03 g, 80%).

2. Synthesis of 4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (1.06 g, 9.6 mmol) in a mixture of dioxane (50 mL)and water (2 mL) was heated to reflux in a two-neck 250 mLround-bottomed flask. A solution of2-methyl-4-isopropylsulfanyl-[1,10]phenanthroline (1.03 g, 3.8 mmol) inhot dioxane (50 mL) was added through an addition funnel over a periodof 30 minutes and the reaction mixture was refluxed for 1 hour. Thereaction mixture was filtered while hot and the residue rinsed with morehot dioxane (20 mL) and filtered. The filtrates were combined andconcentrated in vacuo and the residue was treated with methylenechloride (100 mL) and a 10% K₂CO₃ aqueous solution (100 mL). The aqueouslayer was extracted several times with methylene chloride (3×100 mL) andthe combined organic layers were washed with brine, dried (Na₂SO₄),filtered and concentrated. The crude product was purified by flashchromatography (neutral Al₂O₃, MeOH/DCM, 1:50 to 1:15) to afford thepure product as a light yellow solid (0.44 g, 41%).

3. Synthesis of 4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehydeoxime

The final step to obtain the Compound 7 is carried out in the same wayas described in the synthesis of Compound 4.

¹H NMR (DMSO-d₆, 400 MHz):

11.98 (s, 1H); 9.12 (dd, 1H, J=1.6, 4.0 Hz); 8.51 (dd, 1H, J=1.6, 8.0Hz); 8.35 (s, 1H); 8.12 (d, 1H, J=9.2 Hz); 8.04 (d, 1H, J=9.2 Hz); 8.03(s, 1H); 7.79 (dd, 1H, J=4.0, 8.0 Hz, 1H); 3.89 (m, 1H); 1.46 (d, 6H,J=6.4 Hz)

¹³C NMR (DMSO-d₆, 100 MHz):

151.12; 150.28; 149.13; 146.52; 145.18; 144.81; 136.19; 128.43; 127.11;125.97; 123.52; 121.44; 114.84; 35.40; 22.27

Example 5 Preparation of4-(2-Methoxy-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime(Compound 8) 1. Synthesis of4-(2-Methoxy-ethoxy)-2-methyl-[1,10]phenanthroline

To a suspension of sodium hydride (60% in mineral oil, 1.75 g, 43.7mmol) in THF (30 mL) a solution of 2-methoxyethanol (3.30 g, 43.7 mmol)in anhydrous THF (10 mL) was slowly added. The mixture was stirred atroom temperature for 20 minutes and a solution of4-chloro-2-methyl-[1,10]phenanthroline (2.00 g, 8.8 mmol) in anhydrousTHF (20 mL) was added. The reaction mixture was refluxed for 18 hoursand the solvent was removed in a rotary evaporator. The residue wastreated with methylene chloride (100 mL) and saturated NaHCO₃ (100 mL)and transferred to a separatory funnel. The organic layer was washedwith brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo.The residue was washed with hexane and purified by flash chromatography(SiO₂, MeOH/DCM, 1:30) to afford the pure product as a light yellowsolid (1.17 g, 50%).

2. Synthesis of 4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (1.19 g, 10.8 mmol) in a mixture of dioxane (50 mL)and water (2 mL) was heated to reflux in a two-neck 250 mLround-bottomed flask. A solution of4-(2-methoxy-ethoxy)-2-methyl-[1,10]phenanthroline (1.16 g, 4.3 mmol) inhot dioxane (30 mL) was added through an addition funnel over a periodof 10 minutes and the reaction mixture was refluxed for 30 minutes. Thesolvent was evaporated in vacuo and the residue was treated withmethylene chloride (200 mL) and saturated NaHCO₃ (200 mL). The aqueouslayer was extracted several times with methylene chloride (3×100 mL) andthe combined organic layers were washed with brine, dried (Na₂SO₄),filtered and evaporated. The crude product was purified by flashchromatography (SiO₂, MeOH/DCM, 1:40 to 1:20) to afford the pure productas a pale solid (0.65 g, 53%).

3. Synthesis of 4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehydeoxime

The final step to obtain the Compound 8 is carried out in the same wayas described in the synthesis of Compound 4.

¹H NMR (DMSO-d₆, 400 MHz):

11.94 (s, 1H); 9.06 (dd, 1H, J=1.6, 4.0 Hz); 8.46 (dd, 1H, J=1.2, 8.0Hz); 8.35 (s, 1H); 8.13 (d, 1H, J=8.8 Hz); 7.95 (d, 1H, J=8.8 Hz); 7.75(dd, 1H, J=4.4, 8.0 Hz); 7.57 (s, 1H); 4.43 (t, 2H, J=4.4 Hz); 3.83 (t,2H, J=4.4 Hz); 3.36 (s, 3H)

¹³C NMR (DMSO-d₆, 100 MHz):

161.3; 153.5; 150.3; 150.0; 146.1; 145.0; 136.6; 128.9; 126.4; 123.7;120.5; 119.9; 99.7; 70.2; 68.4; 58.6

Example 6 Preparation of4-(2-Amino-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime (Compound9) 1. Synthesis of[2-(2-Methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]-carbamic acidtert-butyl ester

To a suspension of sodium hydride (60% in mineral oil, 0.87 g, 21.8mmol) in THF (15 mL) a solution of N-Boc-2-hydroxyethylamine (1.75 g,21.8 mmol) in anhydrous THF (5 mL) was slowly added. The mixture wasstirred at room temperature for 20 minutes and a solution of4-chloro-2-methyl-[1,10]phenanthroline (1.00 g, 4.4 mmol) in anhydrousTHF (20 mL) was slowly added. The reaction mixture was refluxed for 18hours and the solvent was removed in a rotary evaporator. The residuewas treated with methylene chloride (100 mL) and saturated NaHCO₃ (100mL) and transferred to a separatory funnel. The organic layer was washedwith brine (100 mL), dried (Na₂SO₄), filtered and concentrated in vacuo.The residue was washed with hexane and purified by flash chromatography(SiO₂, MeOH/DCM, 1:40) to afford the pure product as a pale solid (0.72g, 46%).

2. Synthesis of [2-(2-Formyl-[1,10]phenanthrolin-4-yloxy)-ethyl]carbamicacid tert-butyl ester

A solution of SeO₂ (0.56 g, 5.1 mmol) in a mixture of dioxane (25 mL)and water (2 mL) was heated to reflux in a two-neck 100 mLround-bottomed flask. A solution of[2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]-carbamic acidtert-butyl ester (0.72 g, 2.0 mmol) in hot dioxane (20 mL) was addedthrough an addition funnel over a period of 15 minutes and the reactionmixture was refluxed for 45 minutes. The solvent was evaporated in vacuoand the residue was treated with methylene chloride (100 mL) andsaturated NaHCO₃ (100 mL). The aqueous layer was extracted withmethylene chloride (3×100 mL) and the combined organic layers werewashed with brine, dried (Na₂SO₄), filtered and concentrated. The crudeproduct was obtained as a yellow solid (0.52 g, 69%) and was pure enoughto be used in further synthetic steps without additional purification.

3. Synthesis of 4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehydeoxime

A solution of [2-(2-formyl-[1,10]phenanthrolin-4-yloxy)-ethyl]carbamicacid tert-butyl ester (0.52 g, 1.4 mmol) was stirred for 1 hour at roomtemperature in a mixture of trifluoroacetic acid (5 mL) and methylenechloride (10 mL). The solvent was removed and the residue was dried andredissolved in ethanol (5 mL). A solution of hydroxylamine hydrochloride(0.88 g, 12.7 mmol) in water (7 mL) was added followed by the additionof 10% NaOH until a white precipitate formed. The mixture was heated toreflux for 1 hour, cooled down to room temperature and the whiteprecipitate filtered, washed with cold water and dried. The titlecompound was isolated as a pale solid (37.0 mg, 9%)

¹H NMR (DMSO-d₆, 400 MHz):

12.13 (s, 1H); 9.09 (dd, 1H, J=1.2 Hz, J=4.0 Hz); 8.50 (dd, 1H, J=1.2Hz, J=8.0 Hz); 8.40 (m, 2H); 7.97 (d, 1H, J=8.8 Hz); 7.81 (dd, 1H, J=4.0Hz, J=8.0 Hz); 7.26 (s, 1H); 3.73 (d, 2H, J=9.2 Hz); 3.52 (d, 2H, J=9.2Hz)

¹³C NMR (DMSO-d₆, 100 MHz):

152.72, 150.00, 146.82, 136.29, 128.51, 124.69, 124.00, 120.02, 116.91,104.21, 96.79, 58.68, 45.62

Example 7 Preparation of4-(2-Diethylamino-ethoxy)-[1,10]-phenanthroline-2-carbaldehyde oxime(Compound 10) 1. Synthesis ofdiethyl-[2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]amine

To a suspension of sodium hydride (60% in mineral oil, 5.25 g, 131.1mmol) in anhydrous THF (90 mL) a solution ofN,N-diethyl-2-hydroxyethylamine (15.30 g, 131.1 mmol) in anhydrous THF(60 mL) was slowly added. The mixture was stirred at room temperaturefor 20 minutes and a solution of 4-chloro-2-methyl-[1,10]phenanthroline(6.00 g, 26.2 mmol) in anhydrous THF (90 mL) was slowly added. Thereaction mixture was refluxed for 18 hours and then allowed to cool downto room temperature, quenched with 1N HCl and evaporated. The residuewas redissolved in 1N NaOH (150 mL) and extracted with methylenechloride (3×200 mL). The combined organic layers were dried (Na₂SO₄),filtered and concentrated in vacuo. The residue was washed with hexaneand purified by flash chromatography (SiO₂, MeOH/DCM, 1:40) to yield thepure product as an orange oil (5.1 g, 63%).

2. Synthesis of4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde

A solution of SeO₂ (0.83 g, 7.5 mmol) in a mixture of dioxane (38 mL)and water (3 mL) was heated to reflux in a two-neck 100 mLround-bottomed flask. A solution ofdiethyl-[2-(2-methyl-[1,10]phenanthrolin-4-yloxy)-ethyl]amine (0.93 g,3.0 mmol) in hot dioxane (20 mL) was added through an addition funnelover a period of 15 minutes and the reaction mixture was refluxed for 45minutes. The solvent was evaporated in vacuo and the residue was treatedwith methylene chloride (100 mL) and saturated NaHCO₃ (100 mL). Theaqueous layer was extracted with methylene chloride (3×100 mL) and thecombined organic layers were washed with brine, dried (Na₂SO₄), filteredand concentrated. The crude product was purified by flash chromatography(SiO₂, MeOH/DCM, 1:40) to afford the pure material as a brown solid(0.19 g, 19%).

3. Synthesis of4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime

The final step to obtain the Compound 10 is carried out in the same wayas described in the synthesis of Compound 4.

¹H NMR (DMSO-d₆, 400 MHz):

11.85 (s, 1H); 9.09 (dd, 1H, J=2.0, 4.4 Hz); 8.46 (dd, 1H, J=1.0, 8.0Hz); 8.31 (s, 1H); 8.13 (d, 1H, J=8.8 Hz); 7.96 (d, 1H, J=8.8 Hz); 7.92(s, 1H); 7.75 (dd, 1H, J=4.4, 8.0 Hz); 4.36 (t, 2H, J=5.6 Hz); 2.96 (t,2H, J=5.6 Hz); 2.60 (q, 4H, 7.2 Hz); 1.01 (t, 6H, d=7.2 Hz)

¹³C NMR (DMSO-d₆, 100 MHz):

161.0; 153.3; 150.0; 149.6; 146.1; 145.0; 136.2; 128.6; 126.1; 123.3;120.3; 119.5; 99.3; 67.5; 50.8; 47.1; 12.0

Biology Example 8 Toxicity

The potential effects on cell viability of the assayed compounds areassayed in SH-SY5Y human neuroblastoma cells, by quantification ofLactate dehydrogenase (LDH) activity release. SH-SY5Y humanneuroblastoma cells are seeded into 96-well culture plates at 104cells/well. The medium is then removed and the cells incubated withdifferent concentrations of the compounds during 24 h. The compounds aretested at increasing concentrations starting from 1 μM, in fresh culturemedium, in order to find the minimum concentration at which thecompounds are toxic, up to a maximum of 1 mM. After 24 h, the medium isremoved and cells attached to the bottom of the well are lysed by adding50 μl of Krebs-Hepes; Triton X-100 1% during 5 minutes at roomtemperature. For LDH release quantification, the Roche cytotoxicitydetection kit (Cat. No. 11 644 793 001) is used. The LDH activity ismeasured by its absorbance at 492 nm with reference wavelength 620 nm.

In Table 1, for each compound the maximum concentration at whichtoxicity was tested is indicated in the second column. In the thirdcolumn, it is indicated whether at this maximum concentration thecompound was toxic or not. All the compounds, with the exception ofCompound 3, resulted non-toxic at the concentration for which activitywas found, in most of the cases even at a 1000-fold concentration. Thus,the compounds may be considered non-toxic.

TABLE 1 Maximum concentration tested Compound No. for toxicity Yes/NoCompound 1 1 mM Yes Compound 2 1 mM Yes Compound 3 10 μM Yes Compound 41 mM Yes Compound 5 1 mM Yes Compound 6 1 mM Yes Compound 7 1 mM YesCompound 8 1 mM No Compound 9 10 μM No Compound 10 1 μM Yes Compound 121000 μM No Compound 13 1000 μM No Compound 14 1000 μM Yes Compound 15100 μM Yes Compound 16 10 μM Yes Compound 17 1000 μM Yes Compound 18 10μM Yes Compound 19 10 μM Yes Compound 20 10 μM Yes

Example 9 Protection Against Hydrogen Peroxide-Induced Cell Death

The aim of this assay is to determine the neuroprotective effect of thecompounds of formula (I), when human neuroblastoma cells are exposed tooxidative stress induced by hydrogen peroxide, which is highlydeleterious to the cell and its accumulation causes oxidation ofcellular targets such as DNA, proteins, and lipids leading tomutagenesis and cell death.

SH-SY5Y human neuroblastoma cells are seeded into 96-well culture plateat a density of 104 cells/well. Cells are exposed to differentconcentrations of the compound one hour before the treatment with H₂O₂100 μM during 24 h. 5 mM N-acetylcysteine (NAC), a known anti-oxidantagent was used as a positive control, and preincubated 1 hour before thetreatment with H₂O₂. After 24 h, the medium is removed and cellsattached to the bottom of the well are lysed by adding 50 μl of TritonX-100 1% in Krebs-Hepes during 5 minutes at room temperature. For LDHrelease quantification, Roche cytotoxicity detection kit (Cat. No. 11644 793 001) was used.

The minimum concentration of Compounds I-10 for which protection againstH₂O₂ was determined are shown in Table 2.

TABLE 2 Compound No. Protect. H₂O₂ Compound 1 0.05 μM Compound 2 0.05 μMCompound 3 10 μM Compound 4 0.05 μM Compound 5 5 nM Compound 6 5 nMCompound 7 0.05 μM Compound 8 50 nM Compound 9 5 μM Compound 10 50 nMCompound 12 0.1 μM Compound 13 0.5 μM Compound 14 0.05 μM Compound 150.5 μM Compound 16 0.05 μM Compound 17 5 μM Compound 18 0.05 μM Compound19 0.5 μM Compound 20 0.5 μM

Protection Against 6-OHDA-Induced Cell Death

The aim of this experiment is to determine the protective effect of thecompounds of formula (I) against the toxicity caused by 6-OHDA. Thistoxin induces a cell death similar to which occurs in Parkinson'sdisease, destroying dopaminergic neurons (“MPTP and6-hydroxydopamine-induced neurodegeneration as models for Parkinson'sdisease: neuroprotective strategies”; Grunblatt E, et al.; J. Neurol.2000 April; 247 Suppl 2:1195-102).

Two or three days before the experiment, the SH-SY5Y human neuroblastomacells are seeded into 96-well culture plate at a density of 10⁴cells/well. Cells are exposed to the treatment with 6-OHDA and, finally,cell death is measured by LDH quantification. As positive control weused NAC.

The assay is performed in two different experimental conditions:

Example 10

A) NAC and the compound of formula (I) are preincubated during 2 hoursbefore the treatment with 6-OHDA 75 μM during 16 hours. The assay isperformed in medium containing 10% Foetal bovine serum.

The neuroprotective results against cellular death induced by 6-OHDA areshown in Table 3. For each compound the minimum concentration ofcompound of formula (I) at which a neuroprotective effect is shown.

TABLE 3 Compound No. Protect. 6-OHDA (+FBS) Compound 1  0.5 μM Compound2  0.5 μM Compound 4 0.05 μM Compound 5 0.05 μM Compound 6 0.05 μMCompound 7 0.05 μM Compound 8 0.05 μM Compound 9   5 μM Compound 10 0.05μM Compound 12  0.1 μM Compound 13  0.5 μM Compound 14  0.5 μM Compound16  0.5 μM Compound 18 0.05 μM

Example 11

B) NAC and the compound of formula (I) are preincubated during 1 hourbefore the treatment with 6-OHDA 50 μM during 24 hours. The assay isperformed in a medium without any fetal bovine serum.

The neuroprotective results against cellular death induced by 6-OHDA areshown in Table 4. For each compound the minimum concentration ofcompound of formula (I) at which a neuroprotective effect is shown.

TABLE 4 Compound No. Protect. 6-OHDA (−FBS) Compound 1 0.5 μM Compound 20.5 μM Compound 3  10 μM Compound 4 0.5 μM Compound 5 0.5 μM Compound 60.5 μM Compound 7 0.5 μM Compound 8 0.5 μM Compound 9   5 μM Compound 100.5 μM Compound 12 0.5 μM Compound 13   5 μM Compound 14 0.5 μM Compound16  10 μM Compound 18  10 μM

Example 12 Neuroprotection Against Aβ Toxicity

In order to evaluate potential neuroprotection of compounds, SH-SY5Ycells, cultured in 96-well plates, were pre-treated for 1 hour with thecompound at different concentrations and then exposed 24 hours to 200 μMAβ₂₅₋₃₅ (Neosystem) to induce extensive oxidative stress and cell death.The ability of the compound of protecting against this toxicity is thenevaluated by measuring intracellular LDH, using the colorimetric LDHassay.

It is widely accepted that the neurotoxic activity of Aβ resides withinamino acids 25-35 (see e.g. Yankner B A et al., (1990) Neurotrophic andneurotoxic effects of amyloid β protein: reversal by tachykininneuropeptides; Science 250:279-282).

In Table 5, the minimum concentration at which the tested compoundsshowed neuroprotection against Aβ₂₅₋₃₅ toxicity is shown.

TABLE 5 Compound No. Protect. beta-Amyloid₂₅₋₃₅ Compound 1  5 μMCompound 2 10 μM Compound 4 0.5 μM  Compound 6 10 μM Compound 8 0.5 μM Compound 9  5 μM Compound 10 0.5 μM  Compound 12 10 μM Compound 13  5 μMCompound 14 10 μM Compound 16  5 μM Compound 18 10 μM

Example 13 Inhibition of Aβ(1-40) Secretion

To quantitate Aβ secretion ELISA-based method was used. The assayconsists in detection of antigen by selective monoclonalanti-Aβ-antibodies at two different epitopes forming a“Sandwich-complex”, that is detected by colorimetric measure due to thebinding of a secondary antibody conjugated with peroxidase thatcatalyses the conversion of a substrate or chromogen, TMB, into acoloured product, directly proportional to the peptide quantity in thesample. The Aβ production has been analyzed by ELISA, using acolorimetric commercial kit: Immunoassay Kit Human β Amyloid 1-40(Biosource).

Aβ (1-40) were quantified from cellular supernatants. An APP-transfectedcell line has been employed for the experiments: CHO7W (stablytransfected with human APP₇₅₁ wt cDNA). The cells were grown in aculture medium consisting of DMEM supplemented with 2% Fetal bovineserum, 1% penicillin-streptomycin, 1% L-glutamine and 200 μg/ml G418.Cells are seeded in 96-well culture microplate, at 5000 cells/well andtreatment with different compounds at different concentrations isperformed 24 hour after seeding.

OM99-2 (H-5108, Bachem), a BACE inhibitor, was used as Aβ secretionreduction positive control in all the Aβ secretion studies. The cellswere treated with this compound at 3 μM concentration, culture mediawere collected at 24 hours. At this concentration OM99-2 shows apercentage of Aβ release inhibition between 20 and 60%.

In Table 6 the minimum concentration for each tested compound at whichthe compound inhibits beta-amyloid inhibition is shown.

TABLE 6 Inhibition secretion beta- Compound No. amyloid Compound 1 0.01mM Compound 2 1 mM Compound 4 0.05 mM Compound 5 1 nM Compound 6 10 nMCompound 7 1 nM Compound 8 1 mM Compound 9 10 mM Compound 10 1 mMCompound 12 1 μM Compound 13 10 μM Compound 14 0.01 μM Compound 15 10 μMCompound 16 1 μM Compound 17 10 μM Compound 18 0.1 μM Compound 19 1 μMCompound 20 10 μM

Example 14 Screening Pharmacokinetic Study

The objective of this study is to evaluate the oral bioavailability andthe plasmatic and brain pharmacokinetic parameters after oral andintravenous administration, thus determining if compounds of formula (I)are able to cross the blood brain bather (BBB). In order to measure thelevels of compounds of formula (I) in plasma and brain, mice (C57BL6/J,males of 8-week aged) were dosed with an intravenous administration (1mg/kg) and two oral administrations (20 mg/kg and 200 mg/kg) of thedifferent compounds. Each compound was solved in appropriate excipients.In the case of oral administration, compound was administered by meansof an oral gavage coupled to a syringe. In the intravenousadministration animals, the test item was administered by a singleinjection with a syringe coupled to a 30 G needle.

Two animals were sacrificed (according to internal SOPs and followinganimal handling and welfare guidelines) at each selected extractiontimes (i.e. 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 hours afteradministration), and from each animal, both brain and blood samples wereobtained. Plasma was extracted by centrifugation of the blood samples.Each sample time represents two male mice from which samples wereobtained.

The method for the analysis of plasma and brain samples involvedisolation of the analyte from the biological matrix by proteinprecipitation or solid-phase extraction followed by analysis usingLC-MS/MS. Limits of quantification for these compounds were in the orderof 2-10 ng/mL. The software Winnonlin professional version 5.2 was usedfor the calculation of pharmacokinetic parameters.

Results

In the following tables, the abbreviations have the meaning indicatedbelow:AUC=Area under the curve

T_(1/2)=Half-life

T_(max)=the time after administration of a drug when the maximum plasmaconcentration is reached; when the rate of absorption equals the rate ofeliminationC_(max)=maximum plasma concentration of the drugV. Adm. and Vol. Adm.=volume of administration

1. Group 1-2 mg/kg Intravenous Route

TABLE 7 C_(max) V. Adm. Dose Plasma Compound No. (ml/Kg) (mg/Kg) (ng/ml)T_(1/2) (h) T_(max) AUC Compound 4 2 1.00 78.70 0.22 0.25 36 Compound 71 1.20 104.2 4.47 1.00 319 Compound 8 2 1.00 689.5 1.11 0.25 243.7Compound 10 2 2.00 136.50 8.10 0.08 148

TABLE 8 Dose C_(max) Compound (mg/ Brain T_(1/2) % No. Kg) (ng/g) (h)T_(max) AUC % C_(max) AUC Compound 4 1.00 104.40 0.39 0.25  45.80 132.66127.22 Compound 7 1.20 386.10 NC 0.08 330.50 370.54 103.61 Compound 81.00  36.10 0.18 0.25  10.70  5.24  4.39 Compound 10 2.00  18.7 2.600.08  33.90  13.70  22.91

2. Group 20 mg/kg Oral Route

TABLE 9 C_(max) Compound V. Adm. Plasma Bio- No. (ml/Kg) (ng/ml) T_(1/2)(h) T_(max) AUC availability Compound 4 4  20.75 0.30 0.25  7.24  1.01Compound 7 4 106.50 1.66 0.30 378.10  7.11 Compound 8 4 396.40 3.90 0.25325.20  6.67 Compound 10 4 149.20 4.00 1.00 184.40 12.46

TABLE 10 C_(max) Compound Dose Brain T_(1/2) No. (mg/g) (ng/g) (h)T_(max) AUC % C_(max) % AUC Compound 20 15.40 0.66 0.25 20.00 74.22276.24 4 Compound 20 19.62 0.73 4.00 23.90 41.66  27.76 7 Compound 2024.60 1.80 0.25 13.60  6.21  4.18 8 Compound 20 13.07 NC 1.00 22.00 8.76  11.93 10

3. Group 200 mg/kg Oral Route

TABLE 11 Vol. C_(max) Compound Adm. Plasma T_(1/2) Bio- No. (ml/Kg)(ng/ml) (h) T_(max) AUC availability Compound 4 4  930.70 0.92 0.50 1375.70 19.11 Compound 7 4 1205.20 — 0.50  1696.80  3.19 Compound 8 — —— — — — Compound 10 4 3950.70 3.79 0.50 11478.90 77.56

TABLE 12 Com- C_(max) pound Dose Brain T_(1/2) % % No. (mg/g) (ng/g) (h)T_(max) AUC C_(max) AUC Com- 200 1394.40 0.94 0.50  1537.90 149.82111.79 pound 4 Com- 200 — — — — — — pound 7 Com- 200 — — — — — — pound 8Com- 200 7751.80 — 2.00 95478.00 196.21 831.77 pound 10

Conclusions

Regarding the results shown in previous tables (7-12), all testedcompounds of formula (I) are able to cross the blood brain barrierbecause they are detected in brain. Oral bioavailability is in the rangebetween 7 and 10% at low dose, and is increased significantly at thehigh concentration.

Example 15 Evaluation of the Chelating Ability of Some Compounds ofFormula (I) with Fe(II)

The assays carried out in presence of the chelating ligands Compound 4,Compound 7, Compound 8 and compound 10 demonstrated that the ligands areable to complex the Fe (II), as the spectrum obtained for the mixture ofeach ligand and the iron differs from the sum of the respectiveindividual spectra (see FIGS. 2, 3, 4 and 5).

Example 16 a) Evaluation of the Chelating Ability of Some Compounds ofFormula (I) with Fe (III)

The assays carried out in presence of Fe (III) have demonstrated thatnone of the compounds of formula (I) were able to complex this metal,because no change in the absorbance spectra of the ligand in presence ofFe (III) is observed; as shown in FIG. 1 for compounds 4, 7, 8 and 10.Only one line is observed, as the spectra are overlapping (see FIG. 1).

b) Evaluation of the Chelating Ability of Some Compounds of Formula (I)with Cu (II)

The assays carried out in presence of the chelating ligands Compound 4,Compound 7 and Compound 8 demonstrated that none of the ligands are ableto complex the Cu (II), as the spectrum obtained for the mixture of eachligand and the copper is coincident with the sum of the respectiveindividual spectra (see FIGS. 6 and 7).

c) Evaluation of the Chelating Ability of Some Compounds of Formula (I)with Zn (II)

All of compounds 4, 7, 8, and 10 complexed with Zn(II) to an extent, buthaving a relatively low formation constant and a relatively highdissociation grade, thus showing that the complexes are not too stable(see FIGS. 8, 9,10 and 11).

Summary of the Results

In the formation of complexes between metallic ions and quelatns, thehigher a formation constant and the lower the dissociation grade, themore stable is the complex. Therefore, it may be observed that thecompounds of formula (I) have a high affinity to Fe (II) in comparisonto the rest of metallic ions tested.

TABLE 13 ε Ligand approx. (compound Expecting Dissociation Formation (lmol⁻¹ Metal no.) time pH Stoichiometry grade constant cm⁻¹) Cu(II) 10  2h 7.4 1:1 (ML)  3.8 ± 0.4 4.4 ± 0.6 · 10⁶  400 (l/mol) Zn(II) 4 24 h 7.41:1 (ML)   46 ± 7 2.2 ± 0.6 · 10⁴ 1000 (l/mol) 7 24 h 7.4 1:2 (ML₂) 13.4 ± 0.7 2.2 ± 0.6 · 10¹⁰  840 (l²/mol²) 8  4 h 7.4 1:2 (ML₂)  7.7 ±0.6 1.4 ± 0.6 · 10¹¹ 7100 10  4 h 7.4 1:2 (ML₂)  3.7 ± 0.6 1.7 ± 0.4 ·10¹³ 9400 (l²/mol²) Fe(II) 4 30 min 8* 1:3 (ML₃) 0.147 ± 8.2 ± 0.5 ·10¹² 1.8 · 0.002 10³ 7 60 min 8* 1:3 (ML₃) 0.023 ± 2.0 ± 0.6 · 10¹⁵ 2.8· 0.002 10² 8 Immediate 7.4 1:3 (ML₃) 0.022 ± 4.0 ± 1.3 · 10¹⁷ 1.6 ·0.006 10³ 10 Immediate 7.4 1:3 (ML₃) 0.019 ± 5.0 ± 1.0 · 10¹⁷ 6.7 ·0.004 10³

What is claimed is:
 1. A method of treating or preventing aneurodegenerative or hematological disease or condition, which methodcomprises administering to a patient a therapeutically effective amount,for such treatment or prevention, of at least one compound of formula(I):

wherein R¹ is selected from —S—R³, —O—R⁴ and halogen; R⁷ is selectedfrom —CH═N—OR⁸ or —CHO; R³ and R⁴ are independently selected from thegroup consisting of C₁-C₆ alkyl, C₆-C₁₅ aryl and heteroaryl, each ofwhich is optionally substituted by C₁-C₆ alkyl, C₆-C₁₅ aryl, halogen,—(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxy and/or —NR⁵R⁶, R⁵ and R⁶ beingindependently selected from hydrogen and C₁-C₆ alkyl, R⁸ is selectedfrom hydrogen and C₁-C₆ alkyl; or a salt or solvate or stereoisomer ortautomer thereof.
 2. The method according to claim 1, wherein: R¹ isselected from —S—R³, —O—R⁴ and halogen; R⁷ is selected from —CH═N—OR⁸ or—CHO; R³ and R⁴ are independently a C₁-C₆ alkyl, each of which isoptionally substituted by C₁-C₆ alkoxy and/or —NR⁵R⁶; R⁵ and R⁶ areindependently selected from hydrogen and C₁-C₆ alkyl; and R⁸ is selectedfrom hydrogen and C₁-C₆ alkyl.
 3. The method according to claim 1,wherein the neurodegenerative disease is selected from the groupconsisting of Alzheimer's Disease, Parkinson's Disease, amyotrophiclateral sclerosis (ALS), schizophrenia, Huntington's Disease, braininjuries, stroke, ischemia, multiple sclerosis, epilepsy, Friedreich'sAtaxia, spongiform encephalopathies, amyloidosis, vascular dementia,tauopathies, progressive supranuclear palsy, corticobasal degeneration,frontotemporal lobular degeneration, subacute sclerosing panencephaliticparkinsonism, postencephalitic parkinsonism, pugilistic encephalitis,guam parkinsonism-dementia complex, Pick's disease, frontotemporaldementia, AIDS associated dementia, multiple sclerosis, mood disorders,depression, schizophrenia, and bipolar disorders.
 4. The methodaccording to claim 1, wherein the hematological disease is selected fromthe group consisting of thalassaemia, anaemia, aplastic anaemia,Diamond-Blackfan anemia, sickle cell disease, hematologic disordersrequiring periodic red cell transfusions, myelodysplastic syndrome,iron-induced cardiac dysfunction, iron-induced heart failure, anddiabetes.
 5. The method according to claim 2, wherein the hematologicaldisease is selected from the group consisting of thalassaemia, anaemia,aplastic anaemia, Diamond-Blackfan anemia, sickle cell disease,hematologic disorders requiring periodic red cell transfusions,myelodysplastic syndrome, iron-induced cardiac dysfunction, iron-inducedheart failure, and diabetes.
 6. The method according to claim 1, whereinR⁷ is —CH═N—OR⁸.
 7. The method according to claim 5, wherein R⁸ ishydrogen.
 8. The method according to claim 1, wherein R¹ is —S—R³. 9.The method according to claim 8, wherein R³ is selected from methyl,ethyl, propyl, isopropyl and heteroaryl, said heteroaryl beingoptionally substituted by C₁-C₆ alkyl, C₆-C₁₅ aryl, halogen,—(C═O)NR⁵R⁶, —(C═O)OR⁵, C₁-C₆ alkoxy and/or —NR⁵R⁶.
 10. The methodaccording to claim 9, wherein the heteroaryl group is substituted byC₁-C₃ alkyl.
 11. The method according to claim 1, wherein R¹ is —O—R⁴.12. The method according to claim 11, wherein R⁴ is selected frommethyl, ethyl, and ethyl substituted by an amine of formula —NR⁵R⁶ ormethoxy, wherein each of R⁵ and R⁶ is independently selected fromhydrogen and C₁-C₆ alkyl.
 13. The method according to claim 12, whereinthe amine is primary or tertiary.
 14. The method according to claim 13,wherein the tertiary amine is diethyl-amine.
 15. The method according toclaim 1, wherein the double bond of the oxime group —CH═NOR⁸ presents anE conformation.
 16. The method according to claim 1, wherein R¹ ischloro.
 17. The method according to claim 1, wherein R³ is a C₁-C₃ alkylgroup substituted by —(C═O)NR⁵R⁶ or —(C═O)OR⁵.
 18. The method accordingto claim 1, wherein R⁷ is —CH═N—OR⁸ and R¹ is —S—R³ or —O—R⁴.
 19. Themethod according to claim 1, wherein the compound of formula (I) isselected from the following compounds:4-Methoxy-[1,10]phenanthroline-2-carbaldehyde oxime4-Chloro-[1,10]phenanthroline-2-carbaldehyde oxime4-Chloro-[1,10]phenanthroline-2-carbaldehyde4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde oxime4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime4-(2-Amino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde oxime4-(2-Methoxy-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime2-[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-N,N-dimethyl-acetamide4-(2,2,2-Trifluoro-ethylsulfanyl)-[1,10]phenanthroline-2-carbaldehydeoxime [2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-aceticacid methyl ester4-(Thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehyde oxime[2-(Hydroxyimino-methyl)-[1,10]phenanthrolin-4-ylsulfanyl]-acetic acid4-(5-Methyl-thiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehydeoxime4-(5-Methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehydeoxime4-([1,3,4]Thiadiazol-2-ylsulfanyl)-[1,10]phenanthroline-2-carbaldehydeoxime 4-Methylsulfanyl-[1,10]phenanthroline-2-carbaldehyde4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde4-Propylsulfanyl-[1,10]phenanthroline-2-carbaldehyde oxime4-Ethoxy-[1,10]phenanthroline-2-carbaldehyde4-Isopropylsulfanyl-[1,10]phenanthroline-2-carbaldehyde4-(2-Methoxy-ethoxy)-[1,10]phenanthroline-2-carbaldehyde4-(2-Diethylamino-ethoxy)-[1,10]phenanthroline-2-carbaldehyde or salts,solvates, stereoisomers or tautomers thereof.